Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapaquistat and Simvastatin in Hypercholesterolemia
NCT00286481Phase 3Completed
- Sponsor
- Takeda
- Start
- Mar 2006
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of lapaquistat in hypercholesterolemia (3 arms), sponsored by Takeda. Primary endpoint: Change from Baseline in Low Density Lipoprotein cholesterol at 12 weeks. Started Mar 2006; status: completed.
02
Drugs
lapaquistat
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT00286481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00286481.